Search

Displaying results 1741 - 1750 of 7540 in total
  1. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. … Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[

  2. Drug

    Doxylamine

    go.drugbank.com/drugs/DB00366
    ApprovedInvestigationalVet approved

    Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.

    Mixtures: N - Time, N - Time SinusSynonyms: N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine, Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether
  3. Drug

    Cefditoren

    go.drugbank.com/drugs/DB01066
    Approved

    It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.

  4. Drug

    Gadobenic acid

    go.drugbank.com/drugs/DB00743
    ApprovedInvestigational

    [A263086] It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. … [A1139] Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance.[A263166]

  5. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and [DB05521] but is classified as a second generation protease inhibitor. … This class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs.

  6. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    Interestingly, this drug has been studied for bactericidal properties, however, is not currently, used for this purpose [A32725]. … Experimentation with the drug and its derivatives for recreational purposes has led to many cases of acute toxicity and has been linked to three fatalities.

  7. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … The average age of diagnosis is between age 65 to 74.

  8. Drug

    Flunitrazepam

    go.drugbank.com/drugs/DB01544
    ApprovedIllicit

    Flunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia.

  9. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.

  10. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.